NCT04363463

Brief Summary

The SARS-Cov2 viral pandemic is responsible for a new infectious disease called COVID-19 (CoronaVIrus Disease), is a major health problem. Respiratory complications occur in 15 to 40%, the most serious is acute respiratory distress syndrome (ARDS). The management of COVID-19 is essentially symptomatic with respiratory oxygen supplementation in mild forms to invasive mechanical ventilation in the most severe forms. Prone position (PP) reduced mortality in patients with ARDS in intensive care. Ding et al showed that PP and high flow oxygenation reduced the intubation in patients with moderate to severe ARDS. The investigators hypothesize that the use of PP in spontaneously ventilation patients under oxygen standard could decrease incidence of intubation or non-invasive ventilation or death compared to conventional positioning management in medical departments.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
268

participants targeted

Target at P50-P75 for not_applicable covid19

Timeline
Completed

Started Aug 2020

Typical duration for not_applicable covid19

Geographic Reach
2 countries

19 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 22, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 27, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

August 28, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 13, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 13, 2022

Completed
Last Updated

December 28, 2022

Status Verified

December 1, 2022

Enrollment Period

1.4 years

First QC Date

April 22, 2020

Last Update Submit

December 27, 2022

Conditions

Keywords

COVID19Oxygen therapyProne positionSpontaneous ventilationAcute respiratory failure

Outcome Measures

Primary Outcomes (1)

  • Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups.

    To show that PP in spontaneously ventilation patients could reduce the risk of acquiring the following event (composite endpoint): * Endotracheal intubation * Or non-invasive ventilation (NIV) with two pressure levels * And/or death

    Day 28

Secondary Outcomes (8)

  • Duration in days for the change of 2 points on the WHO ordinal scale

    Day 28

  • Rate (%) of intubation and invasive ventilation in the 2 randomization groups.

    Day 28

  • Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups

    Day 28

  • Duration of oxygen therapy in the 2 randomization groups.

    Day 28

  • Duration of hospitalization in the 2 randomization groups.

    Day 28

  • +3 more secondary outcomes

Study Arms (2)

Conventional positioning

NO INTERVENTION

semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).

Interventional positioning : prone position

EXPERIMENTAL

Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.

Other: prone position

Interventions

Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.

Interventional positioning : prone position

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged from 18 to 85 years old
  • With COVID-19 documentation
  • Undergoing oxygen therapy (nasal cannula, medium or high concentration mask or high flow nasal oxygen therapy)
  • Able to move to PP by him/herself or with minimal assistance
  • Written consent
  • Hospitalized in COVID medical department for less than 72 hours

You may not qualify if:

  • Pregnant (positive pregnancy test during screening) or breastfeeding women
  • Patient on long-term oxygen therapy or Continuous Positive Airway Pressure (CPAP) or Non-Invasive Ventilation (NIV) at home
  • Chronic Obstructive Pulmonary Disease (COPD) Patient stage 3 or 4
  • Patient with known chronic diffuse interstitial lung disease
  • Patient with neuromuscular pathology
  • Contraindication to the PP (recent thoracic trauma, pneumothorax, orthopaedic fracture preventing mobilization, ...)
  • Deep vein thrombosis of the lower limbs or pulmonary embolism with effective anticoagulation for less than 48 hours
  • Hemodynamic instability (MAP \< 65 mm Hg) persisting for more than 1 hour
  • Respiratory rate greater than 40 cycles per minute
  • Excessive use of accessory respiratory muscles (as judged by the clinician)
  • Indication for curative NIV (acute pulmonary edema or acute hypercapnic respiratory failure)
  • Intestinal Occlusive Syndrome
  • Patient unable to protect upper airway
  • Inability to understand French or to follow instructions for the prone position.
  • Person under guardianship
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

CH de Blois

Blois, 41016, France

Location

CH de DAX

Dax, 40100, France

Location

CHD de VENDEE

La Roche-sur-Yon, 85925, France

Location

CH de LA ROCHELLE

La Rochelle, 17019, France

Location

CH Le Mans

Le Mans, 72037, France

Location

CH Mont de MArsan

Mont-de-Marsan, 40012, France

Location

CHR d'Orléans - Service Pneumologie

Orléans, 45000, France

Location

CHR d'Orleans - Service Maladies Infectieuses

Orléans, 45067, France

Location

HOPITAL LARIBOISIERE - Service diabétologie, endocrinologie, nutrition

Paris, 75010, France

Location

Hopital Européen Georges Pompidou

Paris, France

Location

Hopital Lariboisiere - Medecine Interne

Paris, France

Location

Hopital Lariboisiere

Paris, France

Location

CH de PERPIGNAN - Service Maladies infectieuses

Perpignan, 66046, France

Location

Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau

Quimper, 29000, France

Location

CHRU de Tours - Service Médecine interne et immunologie Clinique

Tours, 37000, France

Location

CHRU de Tours - Service Pneumologie

Tours, 37000, France

Location

CHRU DE TOURS - Service Médecine interne et maladies infectieuses

Tours, 37044, France

Location

CH Bretagne Atlantique

Vannes, 56017, France

Location

centre Hospitalier Princesse Grace

Monaco, Monaco

Location

Related Publications (6)

  • Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA. 2020 Apr 21;323(15):1499-1500. doi: 10.1001/jama.2020.3633. No abstract available.

    PMID: 32159735BACKGROUND
  • Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.

    PMID: 31986264BACKGROUND
  • Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.

    PMID: 32171076BACKGROUND
  • Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.

    PMID: 32167524BACKGROUND
  • Nay MA, Hindre R, Perrin C, Clement J, Plantier L, Seve A, Druelle S, Morrier M, Laine JB, Colombain L, Corvaisier G, Bizien N, Pouget-Abadie X, Bigot A, Jamard S, Nyamankolly E, Planquette B, Fossat G, Boulain T. Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial. Crit Care. 2023 Jun 17;27(1):240. doi: 10.1186/s13054-023-04529-z.

  • Nay MA, Planquette B, Perrin C, Clement J, Plantier L, Seve A, Druelle S, Morrier M, Laine JB, Colombain L, Corvaisier G, Bizien N, Pouget-Abadie X, Bigot A, Bernard L, Nyamankolly E, Fossat G, Boulain T. Does awake prone positioning prevent the use of mechanical respiratory support or death in COVID-19 patients on standard oxygen therapy hospitalised in general wards? A multicentre randomised controlled trial: the PROVID-19 protocol. BMJ Open. 2022 Jul 8;12(7):e060320. doi: 10.1136/bmjopen-2021-060320.

MeSH Terms

Conditions

COVID-19Respiratory Distress Syndrome

Interventions

Prone Position

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesRespiration Disorders

Intervention Hierarchy (Ancestors)

PostureMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Mai-Anh NAY, Dr

    CHR Orléans

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Randomized controlled multicenter trial Ratio 1:1
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 22, 2020

First Posted

April 27, 2020

Study Start

August 28, 2020

Primary Completion

January 13, 2022

Study Completion

January 13, 2022

Last Updated

December 28, 2022

Record last verified: 2022-12

Locations